This Komodo Health company profile covers the company's valuation, revenue, funding rounds, investors and history. Komodo Health works in healthcare, with a focus on health data and analytics. It was founded in 2014 and is headquartered in San Francisco, California, United States. Its latest valuation on record is US$3.3 billion (March 2021). Every figure links to a public source, and anything the company hasn't disclosed is marked as such.
Revenue
Funding history
| Date | Round | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Mar 2021 | Series E | US$220M | US$3.3B | Tiger Global and Casdin Capital (leads); ICONIQ Growth, Andreessen Horowitz, SVB Capital | MobiHealthNews |
Komodo Health timeline
Key dates from the sources on this page, oldest first. Metric snapshots are listed after the funding events.
- 2014 — Komodo Health is founded in San Francisco by Arif Nathoo (CEO) and Web Sun.
- Mar 2021 — Series E: US$220M, valuing the company at US$3.3B. Investors: Tiger Global and Casdin Capital (leads); ICONIQ Growth, Andreessen Horowitz, SVB Capital.
Investors
Overview
Komodo Health builds a large map of the US healthcare system from de-identified patient data, including insurance claims and other sources, tracking how patients move through diagnoses, treatments, providers and outcomes over time. Its software applications use this Healthcare Map to help pharmaceutical and medical device companies understand diseases, design clinical trials, identify where patients are treated and measure the real-world performance of therapies, and to help payers and providers analyse care. In March 2021 Komodo raised a US$220 million Series E at a US$3.3 billion valuation, led by Tiger Global and joined by Casdin Capital.
Arif Nathoo, the CEO, and Web Sun founded Komodo Health in 2014. Nathoo, a physician by training, previously worked in healthcare consulting, and Sun previously worked in technology and healthcare analytics. They set out to make healthcare data more useful by connecting fragmented sources into a single, continuously updated view.
Products
- Healthcare Map: a de-identified, longitudinal view of patient journeys across the US healthcare system.
- Analytics applications: software for market analysis, patient finding, clinical trial planning, field sales targeting and health economics.
- MapLab: a platform for data scientists to analyse Komodo's data.
- AI features: tools that let users ask questions of the data in plain language.
Funding
Komodo raised a US$50 million Series C in 2020 and a US$44 million Series D that was disclosed later. In March 2021 it announced a US$220 million Series E led by Tiger Global and joined by Casdin Capital, with existing investors ICONIQ Growth, Andreessen Horowitz and SVB Capital, at a US$3.3 billion valuation. The company said the funds would expand its Healthcare Map, applications and data assets. We haven't found a newer priced round, so the 2021 valuation should be treated as historical.
Business model
Komodo sells subscriptions to its data and software, mainly to pharmaceutical, biotech and medical device companies, along with payers, providers and public health organisations. Large life sciences companies spend heavily on data and analytics for commercial planning, medical affairs and research, and multi-year contracts provide recurring revenue.
Competition
Komodo competes with IQVIA, the largest healthcare data company; with Optum, Symphony Health, HealthVerity and Definitive Healthcare; and with clinical data companies such as Truveta and Flatiron Health. Its strengths are the breadth of its patient journey data and its software applications built on that data.
Komodo Health at a glance
Komodo Health is a San Francisco healthcare data and analytics company founded in 2014 by Arif Nathoo and Web Sun. Its Healthcare Map tracks de-identified patient journeys across the US system, powering software for life sciences, payers and providers. It raised a US$220 million Series E at a US$3.3 billion valuation in March 2021, led by Tiger Global and Casdin Capital.
Timeline
- 2014: founded.
- 2020: raises Series C and Series D.
- March 2021: raises US$220 million at US$3.3 billion.
- 2023–2026: adds AI-driven analytics.
How life sciences companies use patient data
When a pharmaceutical company develops a drug for a rare disease, it needs to know how many patients have the condition, where they're diagnosed and treated, which doctors see them and how they move between treatments. That information shapes clinical trial site selection, sales and medical outreach, and pricing negotiations. After a drug launches, real-world data shows how patients use it and how outcomes compare with alternatives. Komodo's Healthcare Map provides those insights by linking de-identified records across many sources.
Privacy and de-identification
Health data companies in the US rely on de-identified data, which removes personal identifiers under HIPAA rules so it can be used for analysis. Linking records over time without revealing identities requires tokenisation techniques. Privacy advocates have raised concerns about re-identification risks and how health data is bought and sold, and regulators continue to examine the industry. Strong governance and transparency are important for maintaining trust.
Who funds Komodo Health
Komodo's investors include Tiger Global, Casdin Capital, ICONIQ Growth, Andreessen Horowitz, SVB Capital and McKesson Ventures.
Who uses Komodo Health
Komodo's customers include pharmaceutical, biotech and medical device companies, health plans, providers and public health organisations.
Valuation context
Komodo's 2021 valuation was set during the health tech boom. Our guide to health tech unicorns compares it with peers.
Risks
- Competition: IQVIA and others have large data assets.
- Privacy regulation: rules on health data could tighten.
- Customer budgets: life sciences spending can fluctuate.
- Stale valuation: the last mark is from 2021.
Questions for buyers
- How complete is coverage for your disease area?
- How current is the data, and how often is it refreshed?
- How is privacy protected?
The healthcare data industry
Healthcare generates enormous amounts of data from insurance claims, pharmacy transactions, laboratory results and electronic health records. Over decades, an industry has grown up to collect, de-identify, link and analyse that data for pharmaceutical companies, insurers and researchers. IQVIA, formed from the merger of IMS Health and Quintiles, is the largest player. Newer companies such as Komodo, HealthVerity and Truveta have used modern cloud technology and different data sources to compete. Demand is increasing as AI makes it possible to analyse more data and as regulators accept real-world evidence for some decisions about drug safety and effectiveness.
For life sciences companies, these data sets support decisions worth billions of dollars, from which clinical trials to run to how to launch new drugs. That's why they spend heavily on data and analytics, and why providers with differentiated data can command high valuations.
Buyers typically evaluate several data providers on the same research question to compare coverage and accuracy before committing.
Why Tiger Global and Casdin invested
Tiger Global was one of the most active growth investors in 2021, backing many data and software companies at high valuations. Casdin Capital specialises in life sciences and healthcare, bringing sector expertise. Their joint lead reflected the period's enthusiasm for health data platforms.
Data freshness, coverage and ease of use are usually the deciding factors.
Latest developments (October 2026)
Komodo Health made several leadership and partnership moves in 2026: it appointed Amit Sangani as chief technology officer in January and Miles Ennis as president in June, partnered with the advocacy group ZERO Prostate Cancer, and expanded its work with Alnylam Pharmaceuticals to use its Marmot AI analytics platform across the drugmaker, according to company announcements summarised by CB Insights. It has not raised new equity since its 2021 round at US$3.3 billion.
What to watch
Watch AI product launches, partnerships, new funding and privacy regulation.
Takeaways
Life sciences companies can understand patient journeys and markets. Founders can see how data infrastructure supports software products. Investors should treat its valuation as a 2021 mark.
Sources
Every figure on this page comes from the public sources below. Where sources disagreed, we used the company's own announcement or a primary news report. Private-company data changes; check the date beside each figure.
Frequently asked questions
What does Komodo Health do?
Komodo Health is a healthcare / health data and analytics company headquartered in San Francisco, California, United States. It was founded in 2014.
What is Komodo Health's valuation?
Komodo Health was valued at US$3.3 billion as of March 2021, according to MobiHealthNews. Private company valuations are set at funding rounds or share sales and can change significantly between them.
How much revenue does Komodo Health make?
Komodo Health is a private company and has not publicly disclosed its revenue. Figures on third-party sites are usually modelled estimates rather than numbers reported by the company.
What was Komodo Health's latest funding round?
The most recent financing we have verified is a series e in Mar 2021: US$220M, at a valuation of US$3.3B. Source: MobiHealthNews.
Who are Komodo Health's investors?
Investors named in public announcements include Tiger Global, Casdin Capital, ICONIQ Growth, Andreessen Horowitz, SVB Capital and McKesson Ventures.
Who founded Komodo Health?
Komodo Health was founded in 2014 by Arif Nathoo (CEO) and Web Sun.
Is Komodo Health a public company?
No. Komodo Health is a private company (private, venture backed), so its shares are not traded on a stock exchange and it isn't required to publish its financial results.
Where is Komodo Health headquartered?
Komodo Health is headquartered in San Francisco, California, United States.